

# Aortic Disease Summit

Hyatt Regency Baltimore on the Inner Harbor  
September 22–23, 2009

## AGENDA



### Day 1

Tuesday, September 22, 2009

8:00 Continental Breakfast

8:30 Opening Remarks

*Hal Dietz, MD, Johns Hopkins Univ., Howard Hughes Medical Institute, Baltimore, MD*

8:40 GenTAC as an international resource

*Kim Eagle, MD, Univ. of Michigan, Ann Arbor, MI*

#### Session 1 New Insights into the Pathogenesis of Aortic Aneurysm from Disease Genes and Animal Models

*Cheryl Maslen, PhD, Chair*

9:00 Developmental underpinnings of apparently acquired aortic aneurysm

*Hal Dietz, MD, Johns Hopkins Univ., Howard Hughes Medical Institute, Baltimore, MD*

9:20 Perturbation of the VSMC contractile unit and aortic aneurysm: clinical presentation, incidence and mechanism

*Dianna Milewicz, MD, PhD, Univ. of Texas Health Science Center, Houston, TX*

9:40 Notch signaling and aortic disease

*Vidu Garg, MD, Nationwide Children's Hospital, Columbus, OH*

10:00 Angiotensin II induction of thoracic and abdominal experimental aneurysms

*Alan Daugherty, PhD, DSc, Univ. of Kentucky, Lexington, KY*

10:20 Question and Answer

10:35 Break

10:50 Potential Activators of Latent TGF $\beta$  in Marfan syndrome

*Daniel Rifkin, PhD, New York Univ., New York, NY*

11:10 AngII infusion and vascular inflammation through IL6 signaling in the mouse model

*Allan Brasier, MD, Univ. of Texas Medical Branch, Galveston, TX*

11:30 Phenotype-genotype and genotype-functional correlations in inherited aneurysm conditions

*Bart Loeys, MD, PhD, Ghent Univ. Hospital, Ghent Belgium*

11:50 Transcriptional regulation of coronary artery development

*Craig Basson, MD, PhD, Weill Medical College of Cornell Univ., New York, NY*

12:10 Question and Answer

12:30–1:10 Lunch

#### Session 2 Advances in the Imaging and Biomarkers of Aortic Disease

*Kathryn Holmes, MD, MPH, and Jonathan Weinsaft, MD, MA, Co-Chairs*

1:10 Prognostic utility of assessment of aortic wall biomechanics

*João Lima, MD, Johns Hopkins Univ., Baltimore, MD*

1:30 Emerging imaging strategies for aortic disease

*Andrew Arai, MD, National Institutes of Health, Bethesda, MD*

1:50 Biomarker development for assessment of Marfan Syndrome

*Jennifer Van Eyk, PhD, Johns Hopkins Univ., Baltimore, MD*

2:10 The potential for development of a circulating marker for acute aortic dissection: opportunities and challenges

*Toru Suzuki, MD, PhD, Univ. of Tokyo, Tokyo, Japan*

2:30 Question and Answer

2:50 Break

### Session 3 Gaps in the Natural History of Aortic Disease

*Reed Pyeritz, MD, PhD, Chair*

- 3:10 Incidence and outcome of aortic disease in Turner syndrome  
*Michael Silberbach, MD, Doernbecher Children's Hospital, Portland, OR*
- 3:25 Aortic dilation in Turner syndrome: progression over time and response to pharmacologic treatment  
*Carolyn Bondy, MD, National Institutes of Health, Bethesda, MD*
- 3:40 Aging and predisposition in Marfan syndrome  
*Reed Pyeritz, MD, PhD, Univ. of Pennsylvania Medical Center, Philadelphia, PA*
- 4:00 Phenotypic heterogeneity and determinants in aortic aneurysm syndromes  
*Guillaume Jondeau, MD, Hospital Bichat, Paris, France*
- 4:20 Clinical association of intracranial and aortic aneurysms: a shared genetic basis?  
*Dong Kim, MD, Univ. of Texas Health Science Center, Houston, TX*
- 4:40 Population prevalence of TAA and its relation to CV risk factors  
*Richard Devereux, MD, Weill Medical College of Cornell Univ., New York, NY*
- 5:00 Question and Answer
- 5:30 RECEPTION IN PISCES ON THE 15TH FLOOR

## Day 2 Wednesday, September 23, 2009

8:00 Continental Breakfast

### Session 4 Controversies and Opportunities in the Surgical Management of Aortic Disease

*Scott LeMaire, MD, and Howard Song, MD, PhD, Co-Chairs*

- 8:30 Surgical considerations regarding the proximal aorta in bicuspid aortic valve syndrome and other non-Marfan entities  
*Joseph Bavaria, MD, Univ. of Pennsylvania Medical School, Philadelphia, PA*
- 8:45 Early outcomes after valve-sparing root replacement: report from the Aortic Valve Operative Outcomes in Marfan Patients Registry  
*Joseph Coselli, MD, Baylor College of Medicine, Houston, TX*
- 9:00 Utility of the Ross procedure in inherited ascending aortic aneurysm  
*Giovanni Battista Luciani, MD, Univ. of Verona, Verona, Italy*
- 9:20 Current strategies for follow-up and treatment for Ehlers-Danlos syndrome type IV, the "vascular" type  
*Peters Byers, MD, Univ. of Washington, Seattle, WA*
- 9:35 A critical assessment of surgical/interventional practices in vascular EDS  
*James H. Black, MD, Johns Hopkins Univ., Baltimore, MD*
- 9:50 Question and Answer
- 10:10 Break
- 10:30 The role of thoracic endografts in acute aortic syndromes  
*Lars Svensson, MD, PhD, Cleveland Clinic, Cleveland, OH*
- 10:50 Development of rational surgical practices in patients with TGF $\beta$  mutations  
*Duke Cameron, MD, Johns Hopkins School of Medicine, Baltimore, MD*
- 11:10 Question and Answer



**gentAC**

## Session 5 Late-breaking science

*Richard Devereux, MD, Chair*

- 11:20 Deletion of Acta2 Leads to Increased Smooth Muscle Cell Proliferation and Neointimal Formation in Mice  
*Christina L. Papke Univ. of Texas Health Science Center, Houston, TX*
- 11:30 Analysis of TGFbeta Function in Aortic Aneurysms  
*Mohamad Azhar, PhD Univ of Arizona, Tucson, AZ*
- 11:40 Copy number variant analysis of patients with sporadic thoracic aortic aneurysms and dissection: Association of the aortic disease with chromosome 16p13.1 duplications encompassing MYH11 gene  
*Siddharth Prakash, MD, PhD, Baylor College of Medicine, Houston, TX*
- 11:50 Membrane type-1 matrix metalloproteinase plays a multifunctional role in thoracic aortic aneurysm development.  
*Jeffrey A. Jones PhD, Medical University of South Carolina, Charleston, SC*
- 12:00 Smooth muscle cells of fibulin-4 deficient mice contribute to aneurysm progression: An animal model for human thoracic aortic aneurysms  
*Hiromi Yanagisawa, MD, MPH, Univ. of Texas Southwestern Medical Center, Dallas, TX*
- 12:10 Question and Answer

## Session 6 Working Lunch

*Dianna Milewicz, MD, PhD, and Craig Basson, MD, PhD, Co-Chairs*

- 12:20 GentAC investigators and others interested get together and reset registry research priorities based on the presentations given. Where do we need to move the science (current and future)?

## Session 7 Novel Medical Therapeutic Strategies in the Treatment of Aortic Disease

*Hal Dietz, MD, Chair*

- 2:40 AT2 signaling and aortic aneurysm  
*Jennifer Habashi, MD, The Johns Hopkins Hospital, Baltimore, MD*
- 3:00 Novel therapeutic targets in Marfan syndrome  
*Hal Dietz, MD, Johns Hopkins Univ., Howard Hughes Medical Institute, Baltimore, MD*
- 3:20 Emerging therapeutics to attenuate TGFβ signaling  
*John McPherson, PhD, Genzyme Corporation, Cambridge, MA*
- 3:40 Question and Answer
- 4:00 Angiotensin receptor blockers: opportunities and limitations  
*Robert Thompson, MD, Washington Univ. School of Medicine, St. Louis, MO*
- 4:20 Assessment of infrastructure for clinical trials in vascular disease  
*Patrice Desvigne-Nickens, MD, National Heart, Lung and Blood Institute, Bethesda, MD*
- 4:40 Question and Answer
- 5:00 Closing Remarks

*The following organizations provided unconditional grants to help make the Aortic Disease Summit possible:*

*Office of Rare Diseases Research, National Institutes of Health*

*W.L. Gore & Associates, Inc.*

*Medtronic Endovascular Innovations*

*National Marfan Foundation*